Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931256 | 0.90 | ADORA1 (0.41) | MAPTERN1BRAFJAK2JAK1 | |
| SCHEMBL2312296 | 0.88 | MAPT (0.48) | MAPTERN1BRAFBTKRPS6KB1 | |
| SCHEMBL9931440 | 0.88 | JAK2 (0.46) | MAPTERN1BRAFJAK2JAK1 | |
| SCHEMBL9930629 | 0.82 | MAPT (0.44) | MAPTERN1BRAFRPS6KB1MAPK1 | |
| SCHEMBL9931092 | 0.82 | RPS6KB1 (0.51) | MAPTERN1BRAFRPS6KB1AURKA | |
| SCHEMBL9930225 | 0.82 | CHRM4 (0.43) | MAPTERN1BRAFRPS6KB1AURKA | |
| SCHEMBL9931421 | 0.81 | MAPT (0.43) | MAPTERN1BRAFRPS6KB1AURKA | |
| SCHEMBL9930841 | 0.76 | YTHDC1 (0.35) | MAPTBRAFMAPK1ALDH1A1HCAR3 | |
| SCHEMBL9931387 | 0.75 | IRAK4 (0.37) | MAPTRPS6KB1AURKAMAPK1ALDH1A1 | |
| SCHEMBL9930988 | 0.74 | AURKA (0.43) | MAPTERN1BRAFJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPT 1082/4885ERN1 185/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.